BIOCRYST PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense, after Tax
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Share-based Payment Arrangement, Expense, after Tax of $1.61 million for the 3-month period ending 2014-03-31, per its 10-Q filed 2014-05-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax · last filed 2014-05-09
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, expense, after tax for the quarter ending 2014-03-31 was $1.61M, a 0.50% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, expense, after tax for the quarter ending 2013-12-31 was $889.00K, a 8.15% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, expense, after tax for the quarter ending 2013-09-30 was $958.00K, a 17.91% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, expense, after tax for the quarter ending 2013-06-30 was $919.00K, a 18.96% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, expense, after tax for fiscal 2013 was $4.37M, a 4.82% increase from fiscal 2012.
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, expense, after tax for fiscal 2012 was $4.17M, a 12.68% decline from fiscal 2011.
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, expense, after tax for fiscal 2011 was $4.77M, a 24.28% decline from fiscal 2010.
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, expense, after tax for fiscal 2010 was $6.30M.
| Period end | Share-based Payment Arrangement, Expense, after Tax 3 month | Share-based Payment Arrangement, Expense, after Tax 6 month | Share-based Payment Arrangement, Expense, after Tax 9 month | Share-based Payment Arrangement, Expense, after Tax 12 month |
|---|---|---|---|---|
| 2014-03-31 | $1.61M 10-Q · filed 2014-05-09 | $2.50M derived: sum of 2 quarters · filed 2014-05-09 | $3.46M derived: sum of 3 quarters · filed 2014-05-09 | $4.38M derived: sum of 4 quarters · filed 2014-05-09 |
| 2013-12-31 | $889.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | $1.85M derived: sum of 2 quarters · filed 2014-03-10 | $2.77M derived: sum of 3 quarters · filed 2014-03-10 | $4.37M 10-K · filed 2014-03-10 |
| 2013-09-30 | $958.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $1.88M derived: sum of 2 quarters · filed 2013-11-08 | $3.48M 10-Q · filed 2013-11-08 | $4.30M derived: sum of 4 quarters · filed 2014-05-09 |
| 2013-06-30 | $919.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $2.52M 10-Q · filed 2013-08-08 | $3.34M derived: sum of 3 quarters · filed 2014-05-09 | $4.51M derived: sum of 4 quarters · filed 2014-05-09 |
| 2013-03-31 | $1.60M 10-Q · filed 2014-05-09 | $2.42M derived: sum of 2 quarters · filed 2014-05-09 | $3.59M derived: sum of 3 quarters · filed 2014-05-09 | $4.72M derived: sum of 4 quarters · filed 2014-05-09 |
| 2012-12-31 | $822.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | $1.99M derived: sum of 2 quarters · filed 2014-03-10 | $3.12M derived: sum of 3 quarters · filed 2014-03-10 | $4.17M 10-K · filed 2014-03-10 |
| 2012-09-30 | $1.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $2.30M derived: sum of 2 quarters · filed 2013-11-08 | $3.35M 10-Q · filed 2013-11-08 | |
| 2012-06-30 | $1.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $2.18M 10-Q · filed 2013-08-08 | ||
| 2012-03-31 | $1.04M 10-Q · filed 2013-05-09 | |||
| 2011-12-31 | $4.77M 10-K · filed 2014-03-10 | |||
| 2010-12-31 | $6.30M 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |